HGBeyond joins International Research Consortium 3D-NEONET

HGBeyond is one of the partners involved in a new international industry-academia consortium. The 3D-NEONET consortium aims to accelerate the development of therapeutic interventions for cancer and eye disease through enhanced intersectoral and transnational research cooperation.

The consortium is bringing together a unique group of microbiologists, cancer biologists, chemists, material scientists, mechanical engineers, ocular pharmacologists, geneticists and toxicologists from nine academic and nine non-academic partner organisations in seven countries.

The Drug Discovery and Delivery Network for Oncology and Eye Therapeutics (3D-NEONET) consortium has been awarded €945,000, over four years, under the European Union’s Horizon 2020 programme, Marie Skłodowska-Curie Research and Innovation Staff Exchange (MSCA-RISE).

 

3D-NEONET

Drug Discovery and Delivery NEtwork for ONcology and Eye Therapeutics

(H2020-RISE2016/GA734907)

Research and Innovation Staff Exchange

Marie Skłodowska-Curie actions